Protein Antibody & Vaccines World Congress 2024 Europe
Hilton London Kensington, London, United Kingdom
Day 2 - Friday 6th December 2024
- ADCs role in the new wave of investigational drug candidates in this field
- Impact of ADCs on technology development using better linker/payload chemistry and improved processes
PROTEIN AND ANTIBODY ENGINEERING
- ADCs role in the new wave of investigational drug candidates in this field
- Impact of ADCs on technology development using better linker/payload chemistry and improved processes
- Validation testing and reporting strategies and tools
- Influence of interfering factors known to cause false ADA positive signals.
- Framework and a concise reporting structure for NAb assay validations.
- The need for industry-wide alignment that will streamline the review process by regulatory agencies
- Lactic acid bacteria as promising vectors of choice to deliver active molecules to mucosal tissues
- Recent developments on surface-display technologies important for potential industrial applications of lactic acid bacteria
- Recent development of drug discovery targeting “undruggable” proteins and their application in clinic.
- Opportunities for undruggable targets in treatment of human diseases
- Innovative approaches and cutting-edge technologies resulting in several approved drugs and emerging potent chemical entities
- Key considerations that drive the chemical design of protein-based therapeutics
- Well-established and emerging structural and chemical design strategies that have enabled paradigm shift in diseases treatment.
- Areas that need further development to realize the full potential of these molecules
- Review of the development of mRNA peptide display
- How is this technology applied in Drug discovery?
- Addressing the Challenges and future outlook
- Implications of mesotrypsin up-regulation in cancer progression
- Recognition of mesotrypsin’s unique capability on cleavage and inactivation of proteinaceous inhibitors for development of anticancer protein therapeutics
- Overview of the many ways in which ligands can affect GPCR function.
- How this information can be used to develop novel therapeutics against various GPCR targets.
- Challenges and promising opportunities.
- New innovative strategies and tools needed to design, develop, and pharmacologically characterize novel GPCR ligands with the aim of creating better
and more specific drugs.
- Therapeutic antibody development process overview
- Key parameters influencing therapeutic antibody development.
- Innovative tools and methods used to assess product purity and safety throughout therapeutic antibody development.
- Importance of successfully demonstrating safety and efficacy of therapeutic antibodies for regulatory approval and market authorization
